
Increased Risk of Subsequent Meningioma Among Women with Malignant Breast 
Cancer 
Victor Lopez-Rivera, MD, Ping Zhu, MB, MMed, PhD, Antonio Dono, MD, Songmi 
Lee, MS, Peng Roc Chen, MD, Leomar Ballester, MD PhD, Sunil A. Sheth, MD, 
Yoshua Esquenazi, MD 










Please cite this article as: Lopez-Rivera V, Zhu P, Dono A, Lee S, Chen PR, Ballester L, Sheth SA, 
Esquenazi Y, Increased Risk of Subsequent Meningioma Among Women with Malignant Breast Cancer, 
World Neurosurgery (2020), doi: https://doi.org/10.1016/j.wneu.2020.03.203. 
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition 
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of 
record. This version will undergo additional copyediting, typesetting and review before it is published 
in its final form, but we are providing this version to give early visibility of the article. Please note that, 
during the production process, errors may be discovered which could affect the content, and all legal 
disclaimers that apply to the journal pertain. 








Yoshua Esquenazi, MD 
Department of Neurosurgery, Director of Neurosurgical Oncology 
University of Texas Health Science Center at Houston 
6400 Fannin St, Suite 2800 
Houston, Texas 77030 
E-mail: Yoshua.EsquenaziLevy@uth.tmc.edu 
Tel.: 713-486-8000 
Manuscript word count: 2,778 
Number of Tables and Figures: 5 
Number of References: 24 

onflict of Interest: None. 
Disclosure of Funding: None. 

 




















































 
 
 
































The postulated association between breast cancer and meningioma in women has been 
increasingly described over the past decades.1–9 Meningioma tumor growth during pregnancy, 
physiologic changes in the menstrual cycle and use of exogenous hormones have pointed out the 
shared risk factors by these two tumors.1,2,4,10–14 Despite the growing evidence from retrospective 









Cancer Institute collects data on demographics, tumor features, treatment, and survival outcomes 
from approximately 28% of the population in the United States.15 The SEER 18 registries 2000- 














 
 
 



































For a 0-20mm range, a 10mm size was assigned), while those with a possible miscoding (i.e., 
tumor size of 200mm or greater) were included in the unknown group. 




site-specific codes (SEER Program Coding and Staging Manual 2018) for breast and meninges 
and were categorized into 6 groups, respectively. 


















 
 
 
 








































95% confidence intervals [95% CI] for the SIR were calculated using the exact Poisson 
method.16 In addition, we conducted a sensitivity analysis using multivariable binary logistic 



















 
 
 




























































 
 





































with a meningioma significantly increased late in the study (1% vs 16%, 2004 vs 2016; 
P<0.0001) (Supplemental Figure 1). When evaluating the trends in the diagnostic confirmation 

(50% vs 70%, 2004 vs 2016; P=0.0330) while macroscopic/microscopic visualization of the 
tumor was less often used towards the end of the study (50% vs 30%, 2004 vs 2016; P=0.0287). 















the incidence rates of meningioma for age, race, and year of diagnosis when calculating the 
expected number of cases for the SIR calculation.4,6,17 Furthermore, the socio-demographic and 

remained unexplored by these studies. Two previous studies have used the SEER database to 
study the association between these two tumors – Lavrador et al.18 evaluated the survival impact 

 
 
 


































associated with a higher risk of meningioma development in breast cancer patients using the 
SEER database, as in the study by Milano et al.17 the SIR of meningioma was not calculated. The 







is relatively uncommon unless associated with a genetic syndrome, such as neurofibromatosis 
type II.1,14,19 In this age subgroup, the status of ER and PR was positive in 74% and 67% of 


















 
 







































incidence of meningioma between men and women with breast cancer despite the equal rate of 
expression of the estrogen receptor.6,20 Although not found in our study, other studies have 
described the relationship between ER/PR expression in breast carcinoma and meningioma.8,18,21 

previous studies have described that exposure to ionizing radiation (e.g., patients undergoing 
radiotherapy) is a risk factor for meningioma.1,14 In our study, the observed risk of meningioma 


















 






















characteristic radiologic features of meningiomas may serve enough to differentiate from other 
tumors.22–24 
















 
 







































































 































































 










 
 
 







 














Factor, N (%) 
Total 
Socio-demographics 
Age at diagnosis, median (IQR) 
Age group at diagnosis 
18-49 
50-59 
60-69 
70-79 
80- 
Year of diagnosis 
2004-2007 
2008-2011 
2012-2016 
Race/ethnicity 
 Hispanic (All Races) 
 NH American Indian/Alaska Native 
 NH Asian or Pacific Islander 
 NH Black 
 NH Unknown 
 Non-Hispanic White 
Marital status at diagnosis 
 Divorced 
 Married (including common law) 
 Separated 
 Single (never married) 
 Unknown 
 Unmarried or Domestic Partner 
 Widowed 
Insurance 
Uninsured 
Any Medicaid 
Insured/insured, NOS 
Unknown 


None/local tumor destruction 
Partial/subcutaneous mastectomy 
Total/simple/bilateral mastectomy 
Radical mastectomy 
Mastectomy/Surgery, NOS 

Breast CA with 
seq meningioma 
552 (47.6) 
607 (52.4) 
667 (57.5) 
492 (42.5) 

221 (19.1) 
467 (40.3) 
345 (29.8) 
80 (6.9) 
46 (4.0) 
518 (44.7) 
276 (23.8) 
141 (12.2) 
79 (6.8) 
19 (1.6) 
37 (3.2) 
NA 
39 (3.4) 
47 (4.1) 
190 (16.4) 
929 (80.2) 
40 (3.5) 
318 (27.4) 
795 (68.6) 
46 (4.0) 
329 (28.4) 
66 (5.7) 
764 (65.9) 
885 (76.4) 
119 (10.3) 
46 (4.0) 
87 (7.5) 
22 (1.9) 



0.280 
<0.001 





NA= not available. Data from a total of 564,516 patients. Data were suppressed if less than a certain number according to the privacy policy of SEER. 
The Mann-Whitney U test or Pearson's chi-squared test was performed. 

Breast CA without 
seq meningioma 
563357 
Breast CA with 
seq meningioma 
1159 


135586 (24.1) 
143857 (25.5) 
141683 (25.1) 
91357 (16.2) 
50874 (9.0) 
162169 (28.8) 
176114 (31.3) 
225074 (40.0) 
61895 (11.0) 
2403 (0.4) 
46237 (8.2) 
60557 (10.7) 
2895 (0.5) 
389370 (69.1) 
59557 (10.6) 
312597 (55.5) 
5961 (1.1) 
80779 (14.3) 
27104 (4.8) 
1009 (0.2) 
76350 (13.6) 
7537 (1.3) 
51308 (9.1) 
374669 (66.5) 
129843 (23.0) 
37328 (6.6) 
306355 (54.4) 
109059 (19.4) 
107596 (19.1) 
1824 (0.3) 
1195 (0.2) 
186 (16.0) 
250 (21.6) 
351 (30.3) 
246 (21.2) 
126 (10.9) 
505 (43.6) 
424 (36.6) 
230 (19.8) 
92 (7.9) 
NA 
85 (7.3) 
120 (10.4) 
NA 
859 (74.1) 
152 (13.1) 
588 (50.7) 
NA 
142 (12.3) 
52 (4.5) 
NA 
214 (18.5) 
16 (1.4) 
101 (8.7) 
641 (55.3) 
401 (34.6) 
59 (5.1) 
634 (54.7) 
194 (16.7) 
268 (23.1) 
NA 
NA 

<0.001 
<0.001 





None/Unknown 
Yes 

None/Unknown 
Yes 
Tumor features 
Tumor size, median (IQR) 
Tumor size group 
0-9 
10-20 
21-50 
51- 
Unknown 
Tumor stage 
 I 
 IIA 
 IIB 
 IIIA 
 IIIB 
 IIIC 
 IIINOS 
 IV 
 Unknown 

Negative 
Positive 
 Unknown 


Negative 
Positive 
 Unknown 
HER2 status 
Negative 
Positive 
 Unknown 


Infiltrating Duct Ca 
Lobular Ca, NOS 
Infiltrating duct mixed with other Ca 
Infiltrating duct and lobular Ca 
Unknown 
Breast CA without 
seq meningioma 
273987 (48.6) 
289370 (51.4) 
319877 (56.8) 
243480 (43.2) 

103716 (18.4) 
200699 (35.6) 
164587 (29.2) 
40945 (7.3) 
53410 (9.5) 
238911 (42.4) 
124656 (22.1) 
58142 (10.3) 
35909 (6.4) 
11331 (2.0) 
16802 (3.0) 
683 (0.1) 
21000 (3.7) 
55923 (9.9) 
102034 (18.1) 
441138 (78.3) 
20185 (3.6) 
159956 (28.4) 
380236 (67.5) 
23165 (4.1) 
246881 (43.8) 
54529 (9.7) 
261947 (46.5) 
441707 (78.4) 
51424 (9.1) 
18651 (3.3) 
37022 (6.6) 
14553 (2.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



18-49 
50-59 
60-69 
70-79 
80- 
Race/ethnicity 
NH White 
NH Black 
Hispanic 
NH Asian/Pacific Islander 
NH American Indian/Alaska Native 
NH Unknown 
Year of diagnosis 
2004-2007 
2008-2011 
2012-2016 
Marital status 
Single 
Married 
Separated 
Divorced 
Widowed 
Partner 
Unknown 
Insurance status 
Uninsured 
Any Medicaid 
Insured/insured, NOS 
Unknown 

Meningioma, NOS 
Meningothelial meningioma 
Atypical meningioma 
Psammomatous meningioma 
Fibrous meningioma 
Transitional meningioma 

0-9 
10-20 
21-50 
51- 
Unknown/uncertain 

Surgery 
None 
Excision of tumor, lesion, or mass 
Subtotal resection 
Partial resection 
Gross total resection 
Surgery, NOS/Unknown 

None/Unknown 
Yes 

 107 (9) 
224 (19) 
326 (28) 
279 (24) 
223 (19) 
223 (19) 
859 (74) 
120 (10) 
92 (8) 
85 (7) 
NA 
- 
100 (9) 
320 (28) 
739 (64) 
155 (13) 
535 (46) 
127 (11) 
NA 
259 (22) 
NA 
70 
14 (1) 
895 (77) 
151 (13) 
44 (4) 
1015 (88) 
55 (5) 
27 (2) 
18 (2) 
17 (1) 
14 (1) 
106 (9) 
343 (30) 
314 (26) 
54 (5) 
342 (30) 
23 (2) 
810 (70) 
223 (19) 
45 (4) 
51 (5) 
22 (3) 
NA 
1062 (92) 
97 (8) 
NA= not available. Data from a total of 1,159 patients. Data were suppressed if less than a certain number according to 
the privacy policy of SEER. 
 
 
 
 
 
 
 
 
 

Factor 
Total 
Age group at diagnosis 
18-49 
50-59 
60-69 
70-79 
80- 
Race/ethnicity 
NH White 
NH Black 
NH American Indian/Alaska 
NH Asian/Pacific Islander 
Hispanic 
Marital status 
Single 
Married 
Separated 
Divorced 
Widowed 
Partner 
Insurance status 
Uninsured 
Any Medicaid 
Insured 
Insured, NOS 
Tumor stage 
 I 
 IIA 
 IIB 
 IIIA 
 IIIB 
 IIIC 
 IV 
ER status 
Negative 
Positive 
 Borderline 
PR status 
Negative 
Positive 
P 
<0.05 
<0.05 
<0.05 
<0.05 
NS 
NS 
<0.05 
<0.05 
NS 
<0.05 
NS 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
NS 
NS 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
3-11 months 
95%CI 
1.74-2.26 
2.46-5.02 
2.24-3.81 
1.61-2.64 
0.88-1.68 
0.99-2.03 
1.63-2.23 
0.81-2.22 
0-10.3 
1.72-4.46 
2.00-4.18 
1.76-3.55 
1.66-2.41 
0.03-5.92 
1.28-2.97 
1.20-2.26 
0.16-34.98 
1.03-9.69 
2.44-5.04 
1.62-2.31 
0.97-2.35 
1.24-1.93 
1.38-2.48 
1.83-3.88 
1.54-4.22 
0.44-4.18 
1.09-4.99 
3.32-8.20 
1.80-3.30 
1.66-2.24 
0-33.39 
SIR 
1.99 
3.57 
2.95 
2.08 
1.23 
1.44 
1.91 
1.39 
0.00 
2.86 
2.94 
2.54 
2.01 
1.06 
2.00 
1.67 
6.28 
3.78 
3.57 
1.94 
1.55 
1.56 
1.87 
2.72 
2.64 
1.63 
2.53 
5.37 
2.46 
1.94 
0.00 
2.38 
1.91 
1.87-2.99 
1.61-2.24 
P 
<0.05 
<0.05 
<0.05 
<0.05 
NS 
NS 
<0.05 
NS 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
12-59 months 
95%CI 
1.10-1.30 
P 
<0.05 
1.53-2.57 
1.14-1.68 
1.07-1.47 
0.85-1.20 
0.81-1.19 
1.06-1.29 
1.07-1.77 
0-2.60 
1.20-2.21 
0.72-1.35 
1.08-1.72 
0.97-1.24 
0.29-2.72 
1.27-2.00 
0.97-1.41 
0-9.38 
1.04-4.33 
1.33-2.29 
1.05-1.32 
0.73-1.27 
0.93-1.19 
1.11-1.54 
1.12-1.83 
1.03-1.97 
0.57-2.18 
1.09-2.70 
0.76-2.34 
1.02-1.54 
1.10-1.32 
0-6.89 
<0.05 
<0.05 
<0.05 
NS 
NS 
<0.05 
<0.05 
NS 
<0.05 
NS 
<0.05 
NS 
NS 
<0.05 
NS 
NS 
<0.05 
<0.05 
<0.05 
NS 
NS 
<0.05 
<0.05 
<0.05 
NS 
<0.05 
NS 
<0.05 
<0.05 
NS 
1.03-1.42 
1.10-1.34 
<0.05 
<0.05 
SIR 
1.20 
2.00 
1.39 
1.26 
1.02 
0.99 
1.17 
1.39 
0.00 
1.65 
1.00 
1.37 
1.10 
1.06 
1.61 
1.18 
0.00 
2.28 
1.77 
1.18 
0.97 
1.06 
1.31 
1.44 
1.44 
1.18 
1.77 
1.39 
1.26 
1.20 
0.00 
1.21 
1.21 
SIR 
1.10 
1.46 
1.26 
1.13 
1.04 
1.00 
1.12 
1.31 
3.22 
1.14 
0.66 
0.98 
1.06 
1.77 
1.39 
1.03 
0.00 
2.05 
1.17 
1.14 
1.24 
1.00 
1.17 
1.49 
1.34 
1.08 
1.32 
1.80 
1.00 
1.12 
1.69 
1.05 
1.13 
4 
60 months - 
95%CI 
0.99-1.21 
0.85-2.34 
0.97-1.62 
0.92-1.38 
0.85-1.25 
0.08-1.22 
0.99-1.25 
0.94-1.79 
0.66-0.94 
0.71 - 1.72 
0.40-1.04 
0.69-1.35 
0.93-1.22 
0.58-4.14 
1.03-1.83 
0.79-1.32 
0.00-1.25 
0.42-5.99 
0.62-2.00 
0.95-1.37 
0.82-1.80 
0.86-1.15 
0.81-1.26 
1.10-1.98 
0.86-1.97 
0.35-2.51 
0.61-2.51 
0.59-4.21 
0.75-1.29 
1.00-1.25 
0.04-9.39 
0.85-1.28 
0.99-1.27 
P 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<0.05 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<0.05 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
Total 
95%CI 
1.19-1.33 
SIR 
1.26 
2.16 
1.56 
1.32 
1.05 
1.04 
1.24 
1.36 
1.11 
1.62 
1.13 
1.38 
1.19 
1.33 
1.57 
1.20 
1.75 
2.47 
1.95 
1.29 
1.13 
1.09 
1.27 
1.62 
1.55 
1.22 
1.74 
2.39 
1.31 
1.26 
0.81 
1.30 
1.27 
1.78-2.61 
1.36-1.77 
1.18-1.47 
0.93-1.18 
0.91-1.18 
1.16-1.32 
1.13-1.63 
0.23-3.24 
1.29-2.00 
0.91-1.39 
1.16-1.62 
1.10-1.29 
0.64-2.44 
1.33-1.84 
1.04-1.37 
0.04-9.76 
1.41-4.02 
1.59-2.37 
1.19-1.40 
0.92-1.37 
1.00-1.19 
1.12-1.43 
1.37-1.91 
1.23-1.93 
0.74-1.91 
1.23-2.39 
1.71-3.25 
1.13-1.50 
1.19-1.35 
0.02-4.50 
1.16-1.44 
1.18-1.36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Borderline 
HER2 status (2010+) 
Negative 
Positive 
 Borderline 
 HR/HER2 status (2010+) 
 HR+/HER2+ 
 HR-/HER2+ 
 HR+/HER2- 
 HR-/HER2- 
RT 
 
None/Unknown 
Yes 

None/Unknown 
Yes 

<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 












1.89 
2.43 
0.68 
2.31 
2.74 
1.81 
2.47 
2.05 
1.92 
1.57 
2.85 
1.53-2.29 
1.51-3.72 
0.02-3.81 
1.26-3.88 
1.10-5.65 
1.45-2.24 
1.38-4.07 
1.70-2.45 
1.58-2.32 
1.31-1.88 
2.33-3.44 
<0.05 
<0.05 
NS 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
<0.05 
1.29 
1.42 
1.04 
1.36 
1.59 
1.28 
1.38 
1.01 
1.28 
1.05 
1.49 
1.13-1.46 
1.02-1.94 
0.34-2.42 
0.90-1.98 
0.85-2.72 
1.11-1.46 
0.91-2.01 
<0.05 
<0.05 
NS 
NS 
NS 
<0.05 
NS 
0.97-1.25 
1.15-1.43 
NS 
<0.05 
0.94-1.17 
1.31- 1.69 
NS 
<0.05 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1.20 
1.01 
1.03 
1.22 
1.04-1.39 
0.87-1.17 
<0.05 
NS 
0.90-1.17 
1.04- 1.43 
NS 
<0.05 
1.41 
1.63 
0.94 
1.55 
1.83 
1.38 
1.65 
1.26 
1.25 
1.11 
1.54 
1.26-1.57 
1.25-2.09 
0.34-2.04 
1.12-2.11 
1.12-2.83 
1.23-1.55 
1.19-2.22 
1.16-1.37 
1.16-1.36 
1.02-1.19 
1.41-1.69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
